other material
confidence high
sentiment negative
materiality 0.85
Sionna's SION-719 Phase 2a misses sweat chloride endpoint; program halted as add-on
Sionna Therapeutics, Inc.
- SION-719 Phase 2a missed key endpoint: -1.0 mmol/L placebo-adjusted sweat chloride change (p=0.7); not advancing as add-on to SOC.
- Phase 1 of SION-451 dual combos met safety/PK goals; SION-451 + SION-2222 preferred; evaluating next steps.
- Q2 cash $268.3M; plans to preserve capital while assessing SION-451 program.
- SION-719 was well tolerated; no serious AEs; potential confounders (variability, Trikafta exposure) under review.